Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 5/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25387395 | 1.00 | TYMS (0.39) | TYMSDYRK1AKDM4EALDH1A1LMNA | |
| SCHEMBL25388812 | 0.81 | TYMS (0.41) | TYMSDYRK1A | |
| SCHEMBL24233231 | 0.81 | TYMS (0.41) | TYMSDYRK1A | |
| SCHEMBL25390380 | 0.76 | TYMS (0.43) | TYMS | |
| SCHEMBL25390339 | 0.74 | MAPT (0.33) | KDM4EALDH1A1LMNAGLA | |
| SCHEMBL12820951 | 0.72 | DYRK1A (0.46) | TYMSDYRK1A | |
| SCHEMBL18520454 | 0.71 | DYRK1A (0.47) | TYMSDYRK1AKDM4EALDH1A1LMNA | |
| SCHEMBL21161374 | 0.70 | TYMS (0.49) | TYMS | |
| SCHEMBL24704369 | 0.69 | DYRK1A (0.46) | TYMSDYRK1AKDM4EALDH1A1LMNA | |
| SCHEMBL12884842 | 0.69 | TYMS (0.46) | TYMSDYRK1AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286987-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286987-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2023-09-14 | — | — | US | disclosed |
| WO-2022023433-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286987-A1 | COMPOUNDS | HAX1, NHERF1, CXCR1 | TYMS 4374/4885DYRK1A 1006/4885KDM4E 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.